Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 9;29(1):27.
doi: 10.1007/s10006-024-01316-0.

Survival benefit of cancer-directed surgery and the role of adjuvant therapy in malignant major salivary gland cancers: a propensity score matched retrospective analysis

Ahmed Elkoumi  1   2 , Omar Elkoumi  3   4 , Mohamed Hamouda Elkasaby  5   4 , Huzifa Khitiy  6   4 , Mariam Khaled Elbairy  3 , Ahmed Tawfik  7   4 , Omar K Habib  8   4 , Abeer Shaalan  9
Affiliations

Survival benefit of cancer-directed surgery and the role of adjuvant therapy in malignant major salivary gland cancers: a propensity score matched retrospective analysis

Ahmed Elkoumi et al. Oral Maxillofac Surg. .

Abstract

Background: The primary objective of this study was to assess the benefit of cancer-directed surgery (CDS) on both overall survival (OS) and cancer-specific survival (CSS) of patients with malignant major salivary gland cancers (MMSGCs). The secondary objective was to explore the benefits of adjuvant therapy on the survival outcomes of these patients.

Methods: Patients diagnosed with MMSGC were extracted from the SEER database and subsequently categorized into two cohorts: CDS and non-CDS. Propensity score matching (PSM) was used to mitigate confounding variables. The survival benefit associated with CDS was evaluated using Kaplan-Meier analysis, log-rank tests, and Cox proportional hazard models. Furthermore, the impact of adjuvant radiotherapy and chemotherapy was explored within the CDS subgroup.

Results: A total of 7,029 patients with MMSGC were included. PSM was performed and resulted in a matched cohort between both groups, including 595 patients in each group. Multivariable Cox proportional hazard indicated that patients who received CDS had better OS (HR: 0.45, 95% CI [0.39 to 0.52], P < 0.001) and CSS (HR: 0.46, 95% CI [0.40 to 0.52], P < 0.001). The 5- and 10-year OS for the CDS group was 42% (95% CI, 38 - 46%), and 25% (95% CI, 21 - 29%) consecutively, while the 5- and 10-year OS for the non-CDS group was 20% (95% CI, 17 - 24%), and 12% (95% CI, 9.7 - 16%) consecutively. Moreover, patients with younger age, localized tumors, and lower TNM stage could benefit more from CDS. Radiotherapy as adjuvant therapy was found to be beneficial (HR: 0.69, 95% CI [0.55-0.85], p < 0.001), while chemotherapy could not significantly benefit these patients.

Conclusion: CDS improved the OS and CSS survival in MMSGC patients. Specific patient subgroups seemed to have a superior benefit from CDS. Adjuvant radiotherapy could help enhance the survival outcomes of these patients while chemotherapy could not.

Keywords: Adjuvant therapy; Cancer-directed surgery; Propensity score matching; Salivary gland cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Since the SEER database is publicly available, ethical approval is not needed. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

References

    1. Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24(17):2673–2678. https://doi.org/10.1200/JCO.2005.05.3025 - DOI - PubMed
    1. Guzzo M, Locati LD, Prott FJ, Gatta G, Mcgurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148 - DOI - PubMed
    1. Helen Lin H, Limesand KH, Ann DK (2018) Current State of Knowledge on Salivary Gland Cancers. Crit Rev Oncog 23(3–4):139–151. https://doi.org/10.1615/CritRevOncog.2018027598 - DOI - PubMed
    1. Mantravadi AV, Moore MG, Rassekh CH (2019) AHNS series: Do you know your guidelines? Diagnosis and management of salivary gland tumors. Head Neck 41(2):269–280 - DOI - PubMed
    1. Reeve BB, Smith AW, Arora NK, Hays RD Reducing Bias in Cancer Research: Application of Propensity Score Matching. Health Care Financ Rev [Internet]. 2008 Jun [cited 2024 Mar 24];29(4):69. Available https://pmc.ncbi.nlm.nih.gov/articles/PMC4195028/

LinkOut - more resources